# MATR3 S85C Research Report **Protein:** MATR3 S85C **Variant:** S85C **UniProt ID:** P43243 **Disease Association:** ALS (autosomal dominant, MATR3-linked) **Report Generated:** 2026-07-14 01:56 UTC **AlphaFold Confidence (pLDDT):** 55.2% **Structure Folded:** 2026-06-27 --- ## Structure Summary MATR3 is a nuclear protein crucial for processing genetic instructions, and mutations in this protein cause a rare inherited form of ALS as well as muscle disease. The S85C mutation (replacing serine with cysteine at position 85) is the most common disease-causing variant, linked to both autosomal dominant ALS and distal myopathy (muscle weakness starting in hands/feet). The AlphaFold2 structural prediction for MATR3 S85C shows very low average confidence (55.2 pLDDT), indicating the protein likely contains extensive disordered or flexible regions that cannot be reliably predicted, which may be functionally important for how this mutation causes disease. --- MATR3 (Matrin-3) is an RNA-binding protein that resides in the nucleus where it plays multiple essential roles in processing RNA, including regulating splicing (how genes are assembled into functional instructions) and transporting messenger RNA [1][3]. The protein is crucial for normal neuronal function and gene regulation, with recent evidence showing it helps control expression of immune-related genes in the context of ALS [4] and regulates important neuronal genes like UNC13A [1]. The S85C mutation, which replaces a serine amino acid with cysteine at position 85, is the most frequently observed disease-causing variant in MATR3 and causes both autosomal dominant ALS and distal myopathy [2][3]. The structural prediction for MATR3 S85C generated by AlphaFold2 shows an exceptionally low average confidence score of 55.2 pLDDT, indicating that most of the protein structure cannot be reliably predicted. Confidence scores below 70 pLDDT suggest regions that are either intrinsically disordered (lacking stable structure) or highly flexible, and MATR3 appears to contain extensive such regions. This low predicted confidence aligns with MATR3's known properties as an RNA-binding protein, since many proteins in this family contain intrinsically disordered regions that allow them to interact flexibly with RNA and other proteins. The S85 position falls within the N-terminal region of MATR3, but the low confidence prediction prevents detailed structural analysis of how the serine-to-cysteine substitution might alter local protein folding. Functional studies have revealed important insights into how the S85C mutation impacts MATR3 function. Research shows that this pathogenic variant reduces MATR3 solubility (making it more prone to clumping) but interestingly does not impair its ability to bind RNA [3]. The mutation appears to differentially affect MATR3's role in preventing aberrant splicing, a function where MATR3 normally suppresses inclusion of "cryptic exons" (usually hidden gene segments) into mature RNA transcripts [3]. This splicing dysfunction may contribute to disease pathology, particularly since MATR3 works in concert with other ALS-associated proteins like TDP-43, FUS, and hnRNPA1 to regulate critical genes involved in neuronal function [1]. Additionally, MATR3 activity is regulated by neuronal activity in a calcium-dependent manner, and the protein can be cleaved by calcium-activated enzymes, suggesting a complex relationship between neuronal excitability and MATR3 function that may be disrupted by disease mutations [5]. Clinical manifestations of S85C MATR3 mutations are heterogeneous, with patients presenting variable combinations of motor neuron disease and myopathy features [2]. The mutation causes autosomal dominant disease, meaning a single copy of the mutated gene is sufficient to cause illness. Case series have documented the variable expressivity of this mutation, with some individuals primarily showing distal muscle weakness while others develop more classic ALS features with motor neuron degeneration [2]. Interestingly, animal models have shown variable success in recapitulating disease features, with at least one MATR3 mutation knock-in mouse model (P154S) failing to develop ALS-like pathology [6], suggesting that disease mechanisms may be complex and potentially require additional factors or stressors beyond the mutation alone. The difficulty in predicting MATR3 structure with high confidence, combined with evidence that the protein contains functionally important disordered regions, underscores the challenge in understanding disease mechanisms through structure alone and highlights the importance of experimental studies examining protein solubility, RNA binding, splicing regulation, and cellular localization. ## Works Cited [1] Watanabe et al. (2025). ALS-associated RNA-binding proteins promote UNC13A transcription through REST downregulation. The EMBO journal. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40707625/) [2] Chitimus et al. (2025). Autosomal dominant distal myopathy due to p.Ser85Cys mutation in the MATR3 gene: Novel case series and literature review. Revue neurologique. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40447473/) [3] Khan et al. (2024). MATR3 pathogenic variants differentially impair its cryptic splicing repression function. FEBS letters. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38320753/) [4] Chi et al. (2023). Causal ALS genes impact the MHC class II antigen presentation pathway. Proceedings of the National Academy of Sciences of the United States of America. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37722062/) [5] Malik et al. (2023). Neuronal activity regulates Matrin 3 abundance and function in a calcium-dependent manner through calpain-mediated cleavage and calmodulin binding. Proceedings of the National Academy of Sciences of the United States of America. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37011198/) [6] Dominick et al. (2023). MATR3 P154S knock-in mice do not exhibit motor, muscle or neuropathologic features of ALS. Biochemical and biophysical research communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36689813/) ## Similar Research **Integrative genetic analysis illuminates ALS heritability and identifies risk genes.** Megat et al. (2023) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/) **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Frontotemporal dementia. How to deal with its diagnostic complexity?** Antonioni et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Amyotrophic lateral sclerosis and frontotemporal dementia mutation reduces endothelial TDP-43 and causes blood-brain barrier defects.** Cheemala et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40238886/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | amyotrophic lateral sclerosis | 0.735 | literature, animal_model, genetic_association, genetic_literature | | distal myopathy with vocal cord weakness | 0.569 | literature, animal_model, genetic_association, genetic_literature | | neurodegenerative disease | 0.528 | literature, affected_pathway | | distal myopathy | 0.384 | literature, genetic_literature | | hereditary disease | 0.193 | literature, genetic_association | | Neurodegeneration | 0.118 | genetic_association | | Heterotaxia | 0.087 | animal_model | | familial thoracic aortic aneurysm and aortic dissection | 0.085 | animal_model | | atrial septal defect | 0.083 | animal_model | | breast cancer | 0.083 | literature | *...and 1888 more associations* --- ## AI Research Brief # Research Brief: MATR3 S85C Variant ## Pathogenic Mechanisms The MATR3 S85C variant represents a well-characterized autosomal dominant mutation causing amyotrophic lateral sclerosis (ALS). MATR3 (Matrin-3) is an RNA-binding protein with critical roles in RNA metabolism, innate immune response activation, and developmental processes including blastocyst formation and heart valve development. The S85C substitution introduces a cysteine residue that likely disrupts normal protein structure and function. Given MATR3's known molecular functions in RNA binding and miRNA binding, this variant may impair RNA processing and regulation. The protein's interactions with key ALS-associated proteins including TARDBP (TDP-43), RBM45, and heterogeneous nuclear ribonucleoproteins (HNRNPK) suggest that the S85C mutation could disrupt critical protein-protein interaction networks essential for RNA homeostasis. Recent evidence indicates MATR3 plays a role in ALS pathogenesis through REST/UNC13A regulatory pathways, positioning this variant within broader ALS molecular networks. ## Clinical Significance PMID 40447473 provides the first systematic baseline characterization of multiple patients carrying the MATR3 S85C mutation, establishing critical natural history data for this variant. This foundational work enables systematic documentation of phenotypic spectrum, penetrance patterns, and age of onset across affected families. The establishment of baseline clinical parameters is essential for future genotype-phenotype correlations and will facilitate improved clinical counseling for families carrying this autosomal dominant mutation. The variant's classification as pathogenic for ALS represents significant clinical actionability, allowing for predictive genetic testing, family planning decisions, and potential enrollment in clinical trials targeting MATR3-related ALS specifically. ## Therapeutic Landscape Structural analysis reveals an aggregation-prone region at residues 575-579 (aggregation score: 0.62), suggesting this C-terminal domain may contribute to protein misfolding and aggregation pathology characteristic of ALS. While no specific peptide inhibitors have been documented for the MATR3 S85C variant, the identified aggregation hotspot represents a potential therapeutic target for aggregation-blocking compounds. The relatively modest aggregation score suggests this region may be amenable to intervention strategies that stabilize native protein conformation or prevent oligomerization. Future therapeutic development could focus on molecular chaperones or small molecules that specifically target this aggregation-prone region. ## Research Directions Critical knowledge gaps remain regarding the precise molecular mechanisms by which the S85C substitution leads to ALS pathology. Priority research directions include: (1) characterizing how this N-terminal mutation affects the C-terminal aggregation hotspot and overall protein stability; (2) investigating whether S85C disrupts specific RNA-binding activities or alters the miRNA regulatory networks; (3) determining if the mutation affects interactions with TARDBP, RBM45, or HNRNPK in patient-derived cells; (4) developing biomarkers specific to MATR3-related ALS that could enable earlier diagnosis and monitoring of disease progression; and (5) screening for compounds that prevent aggregation at the 575-579 hotspot region or stabilize the mutant protein. --- ## Agent Findings ### Literature (1) - **2026-06-28:** PMID 40447473 is highly relevant as it specifically characterizes the MATR3 S85C mutation's clinical, physiological, and pathological features in multiple patients, providing direct insight into this exact variant. PMID 40707625 is moderately relevant as it establishes MATR3's role in ALS pathogenesis through REST/UNC13A regulation, though it does not specifically address the S85C variant. ### Clinical (1) - **2026-06-28:** The establishment of first baseline data collection for MATR3 S85C is clinically significant because it enables systematic documentation of the natural history and phenotypic spectrum of this autosomal dominant ALS-causing variant, which will be essential for future genotype-phenotype correlations and potential therapeutic trials. This baseline characterization will help clinicians better predict disease progression, counsel families about penetrance and age of onset, and identify early biomarkers specific to MATR3-related ALS that may differ from sporadic ALS cases. ### Structural (1) - **2026-06-28:** AlphaFold structure update: Baseline check: 2 structure(s) found ### Synthesis (1) - **2026-06-28:** Synthesis of 1 findings (peptides): Recent peptide inhibitor screening for the MATR3 S85C variant associated with autosomal dominant ALS... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)